Clinical Application of Bioprosthesis in China: Current Status and Future

Abstract

China is one of the countries which have a high incidence of heart valvular disease, but the use of biological valve is limited in China before because the majority of patients are young patients suffering from rheumatic heart disease. The biological valve has a good application prospect in China. On the one hand, the new generation of biological valves have been significantly improved in the aspects of anti-calcification treatment, anti-metabolism, material quality control, valve frame mechanics design, and leaflet sewing technology, and the application effect is improved; on the other hand, surgeons should adapt to the new concept changes, and correctly understand and rationally apply biological valves, master valve repair, atrial fibrillation ablation and other techniques, combined with interventional, minimally invasive techniques, etc., according to the specific conditions of the disease and choose the surgery type to ensure the patients’ long-term life quality.

References

[1] Van GeldorpMW, Eric JamiesonWR, KappeteinAP, et al.. Patient outcome after aortic valve replacement with a mechanical or biological prosthesis: weighing lifetime anticoagulant-related event risk against reoperation risk. J Thorac Cardiovasc Surg, 2009, 137(4): 881-886

[2] TakkenbergJJ, van HerwerdenLA, EijkemansMJ, et al.. Evolution of allograft aortic valve replacement over 13 years: results of 275 procedures. Eur J Cardiothorac Surg, 2002, 21(4): 683-691

[3] RahimtoolaSH. Choice of prosthetic heart valve in adults an update. J Am Coll Cardiol, 2010, 55(22): 2413-2426

[4] IsaacsAJ, ShuhaiberJ, SalemiA, et al.. National trends in utilization and in-hospital outcomes of mechanical versus bioprosthetic aortic valve replacements. J Thorac Cardiovasc Surg, 2015, 149(5): 1262-1269

[5] WRITING GROUP MEMBERSLloyd-JonesD, AdamsRJ. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation, 2010, 121(7): e46-e215

[6] NishimuraRA, OttoCM, BonowRO, et al.. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol, 2017, 70(2): 252-289

[7] WangY, ChenS, ShiJW, et al.. Mid- to long-term outcome comparison of the Medtronic Hancock II and bi-leaflet mechanical aortic valve replacement in patients younger than 60 years of age: a propensitymatched analysis. Interact Cardiovasc Thorac Surg, 2016, 22(3): 280-286

[8] WangY, ChenS, HuXJ, et al.. Mid- to Long-term Clinical Outcomes of Hancock II Bioprosthesis in Chinese Population. Chin Med J (Engl), 2015, 128(24): 3317-3323

[9] GlaserN, JacksonV, HolzmannMJ, et al.. Aortic valve replacement with mechanical vs. biological prostheses in patients aged 50–69 years. Eur Heart J, 2016, 37(34): 2658-2667

[10] KanekoT, ArankiS, JavedQ, et al.. Mechanical versus bioprosthetic mitral valve replacement in patients >65 years old. J Thorac Cardiovasc Surg, 2014, 147(1): 117-126

[11] MihosCG, PinedaAM, CapouladeR, et al.. A Systematic Review of Mitral Valve Repair With Autologous Pericardial Leaflet Augmentation for Rheumatic Mitral Regurgitation. Ann Thorac Surg, 2016, 102(4): 1400-1405

[12] AttizzaniGF, OhnoY, CapodannoD, et al.. Extended use of percutaneous edge-to-edge mitral valve repair beyond EVEREST (Endovascular Valve Edge-to-Edge Repair) criteria: 30-day and 12-month clinical and echocardiographic outcomes from the GRASP (Getting Reduction of Mitral Insufficiency by Percutaneous Clip Implantation) registry. JACC Cardiovasc Interv, 2015, 8(1PtA): 74-82

[13] MackMJ, LeonMB, SmithCR, et al.. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet, 2015, 385(9986): 2477-2484

[14] KanekoT, CohnLH, ArankiSF. Tissue valve is the preferred option for patients aged 60 and older. Circulation, 2013, 128(12): 1365-1371

[15] Jorge-HerreroE, Garcia PaezJM. Del Castillo-Olivares Ramos JL. Tissue heart valve mineralization: Review of calcification mechanisms and strategies for prevention. J Appl Biomater Biomech, 2005, 3(2): 67-82